Ardelyx, Inc. attended the ACG2026 event hosted by Rome Foundation and TuesdayNight IBS.
Published
Signal category
Presence & Recognition
Quote
“Attending #ACG2026? Attend this amazing event with Rome Foundation and TuesdayNight IBS!”
— Johannah Ruddy DHSc, MEd, FAIS|Ardelyx, Inc. team
Company
Ardelyx, Inc.
Translating Scientific Breakthroughs into Promise for Patients
- Industry
- Biotechnology Research
- Location
- Waltham, US
- Company size
- 529 employees
Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The company’s pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx works with its partners to develop and commercialize its products outside of the United States. Community Guidelines: https://rb.gy/07ltg3
Founded 2007